… preclinical activity in non-small-cell lung cancer (NSCLC) with EGFR mutations. We aimed
to assess the efficacy of afatinib in patients with lung adenocarcinoma and EGFR mutations. …

… availability of afatinib prior to 1 January 2015 and the use of afatinib having been adopted
as routine care for patients with EGFR mutations. Medical records of consecutive patients who …

… We will discuss the use of afatinib in clinical settings, particularly in patients with NSCLC
harboring common and uncommon EGFR mutations, patients with central nervous system (CNS…

… efficacy data of afatinib for NSCLC harboring uncommon EGFR mutations other than T790M.
… recommend afatinib for first-line therapy in patients harboring uncommon EGFR mutations …

… of how patients with uncommon EGFR mutations respond to ERBB family inhibitors is
needed. Here, we describe the activity of afatinib in patients with uncommon EGFR mutations in …

… recently reported afatinib to be clearly superior over the most effective platinum doublet in
patients with EGFR mutation-positive lung cancer. To fully exploit the clinical activity of afatinib, …

… In conclusion, patients with lung adenocarcinoma with EGFR mutations have significant PFS…
with first-line afatinib compared with cisplatin plus pemetrexed. Afatinib could be considered …

… Secondly, the number of patients harboring uncommon EGFR mutations in our study may …
of afatinib in these patients. A larger sample of patients with uncommon EGFR mutations are …

… The current study is a real-world study of afatinib in patients with EGFRm + … in patients with
NSCLC harboring common EGFR mutations, lower ECOG PS and those receiving afatinib as …

… afatinib to the reversible EGFR TKIs, gefitinib or erlotinib, for the first-line treatment of patients
with locally advanced or metastatic EGFR mutation… in patients with known EGFR mutations. …